Cohen Aubart, F., Emile, J.F., Maksud, P., Galanaud, D., Cluzel, P., Benameur, N., Aumaitre, O., Amoura, Z. and Haroche, J. (2018) Efficacy of the MEK Inhibitor Cobimetinib for Wild-Type BRAF Erdheim-Chester Disease. British Journal of Haematology, 180, 150-153.
https://doi.org/10.1111/bjh.14284

has been cited by the following article:

• TITLE: Thirty-Four Months Control of Frail Patient with Multisystemic Affection Proved Erdheim Chester Disease: A Case Report

  AUTHORS: Emad Mohsen Barsoum, Fiby Samir Boules, May Gamal Ashour, Mohsen Samy Barsoum

  KEYWORDS: Erdheim-Chester Disease, Histiocytoses, Non-Langerhans Cell Histiocytoses

  JOURNAL NAME: Journal of Cancer Therapy, Vol.12 No.12, December 13, 2021

  ABSTRACT: Erdheim-Chester disease (ECD) is a rare non-Langerhans form of histiocytosis characterized by multisystemic involvement. We report a case of a 51-year-old male patient treated with pegylated IFN-α in a monthly schedule with low-dose prednisolone and achieved 34 months of control with minimal side effects.